Evidence map›Paper›PMID 36807559›Full record

ArticleScientific reports2023

Atypical Polycystic Kidney Disease as defined by Imaging.

Ioan-Andrei Iliuta, Aung Zaw Win, Matthew B Lanktree, Seung Heyck Lee, Marina Pourafkari, Fatemeh Nasri, Elsa Guiard, Amirreza Haghighi, Ning He, Alistair Ingram and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. How Does ADPKD Severity Differ Between Family Members?Kidney international reports · 2024
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Ioan-Andrei Iliuta *Division of Nephrology, Department of Medicine, University Health Network and University of Toronto, 8N838, 585 University Avenue, Toronto, ON, M5G 2N2, Canada.
Aung Zaw Win *Department of Medical Imaging, University Health Network and University of Toronto, Toronto, ON, Canada.
Matthew B Lanktree *Division of Nephrology, Department of Medicine, St. Joseph's Healthcare and McMaster University, Hamilton, ON, Canada.
Seung Heyck LeeDivision of Nephrology, Department of Medicine, University Health Network and University of Toronto, 8N838, 585 University Avenue, Toronto, ON, M5G 2N2, Canada.
Marina PourafkariDepartment of Medical Imaging, University Health Network and University of Toronto, Toronto, ON, Canada.
Fatemeh NasriDepartment of Medical Imaging, University Health Network and University of Toronto, Toronto, ON, Canada.
Elsa GuiardDivision of Nephrology, Department of Medicine, University Health Network and University of Toronto, 8N838, 585 University Avenue, Toronto, ON, M5G 2N2, Canada.
Amirreza HaghighiDivision of Nephrology, Department of Medicine, University Health Network and University of Toronto, 8N838, 585 University Avenue, Toronto, ON, M5G 2N2, Canada.
Ning HeDivision of Nephrology, Department of Medicine, University Health Network and University of Toronto, 8N838, 585 University Avenue, Toronto, ON, M5G 2N2, Canada.
Alistair IngramDivision of Nephrology, Department of Medicine, St. Joseph's Healthcare and McMaster University, Hamilton, ON, Canada.
Crystal QuistDivision of Nephrology, Department of Medicine, University Health Network and University of Toronto, 8N838, 585 University Avenue, Toronto, ON, M5G 2N2, Canada.
David HillierCIHR SPOR Can-SOLVE Network, Vancouver, Canada.
Korosh KhaliliDepartment of Medical Imaging, University Health Network and University of Toronto, Toronto, ON, Canada.
York PeiDivision of Nephrology, Department of Medicine, University Health Network and University of Toronto, 8N838, 585 University Avenue, Toronto, ON, M5G 2N2, Canada. york.pei@uhn.ca.
University Health Network · CAUniversity of Toronto · CAMcMaster University · CA

Funding

CIHR PJT-376307
6 · The paper itself

Abstract

Using age- and height-adjusted total kidney volume, the Mayo Clinic Imaging Classification provides a validated approach to assess the risk of chronic kidney disease (CKD) progression in autosomal dominant polycystic kidney disease (ADPKD), but requires excluding patients with atypical imaging patterns, whose clinical characteristics have been poorly defined. We report an analysis of the prevalence, clinical and genetic characteristics of patients with atypical polycystic kidney disease by imaging. Patients from the extended Toronto Genetic Epidemiology Study of Polycystic Kidney Disease recruited between 2016 and 2018 completed a standardized clinical questionnaire, kidney function assessment, genetic testing, and kidney imaging by magnetic resonance or computed tomography. We compared the prevalence, clinical features, genetics, and renal prognosis of atypical versus typical polycystic kidney disease by imaging. Forty-six of the 523 (8.8%) patients displayed atypical polycystic kidney disease by imaging; they were older (55 vs. 43 years; P < 0.001), and less likely to have a family history of ADPKD (26.1% vs. 74.6%; P < 0.001), a detectable PKD1 or PKD2 mutation (9.2% vs. 80.4%; P < 0.001), or progression to CKD stage 3 or stage 5 (P < 0.001). Patients with atypical polycystic kidney disease by imaging represent a distinct prognostic group with a low likelihood of progression to CKD.

Indexed as

Polycystic Kidney, Autosomal DominantRenal Insufficiency, ChronicDisease ProgressionHumansKidneyMutationTRPP Cation ChannelsTRPP Cation Channels

Identifiers

PMID36807559
PMCPMC9941465
OpenAlexW4321378067

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.